NW-301V

DRUG4 trials

Sponsors

TingBo Liang, Tao Zhang, Ting Deng, Peking University

Conditions

Tumor, Solid

Phase 1

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

RecruitingNCT06478251

TingBo LiangTumor, Solid

Start: 2024-02-01End: 2027-06-30Target: 9Updated: 2025-11-25

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

RecruitingNCT06484556

Tao ZhangTumor, Solid

Start: 2024-06-19End: 2027-06-30Target: 9Updated: 2025-07-31

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

RecruitingNCT06484790

Ting DengTumor, Solid

Start: 2024-04-08End: 2027-04-07Target: 9Updated: 2025-11-25

NW-301 TCR-T in Patients With Advanced Solid Tumor

Not yet recruitingNCT06956261

Peking UniversityTumor, Solid

Start: 2025-05-10End: 2027-12-31Target: 44Updated: 2025-05-04